Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
EDIT(NASDAQ:EDIT) EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates
September 2, 2025Clinical Trials
Read more →Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
EDIT(NASDAQ:EDIT) CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.
August 28, 2025Clinical Trials
Read more →Editas Medicine to Participate in Upcoming Investor Conferences
EDITCAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:
August 27, 2025Investor Events
Read more →Editas Medicine Announces Second Quarter 2025 Results and Business Updates
EDITCompany to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026
August 12, 2025Earnings
Read more →Editas Medicine Reports 58% Mean HBG1/2 Promoter Editing At Five Months Using Single-Dose tLNP Delivery in Non-Human Primates
EDITJune 12, 2025
Read more →Editas Medicine Unveils New In Vivo Data Highlighting Potential of Editas' Gene Upregulation Strategy In HSCs At American Society of Gene and Cell Therapy Annual Meeting
EDITMay 14, 2025
Read more →Baird Maintains Outperform on Editas Medicine, Lowers Price Target to $4
EDITMay 13, 2025
Read more →Editas Medicine Shares In Vivo Proof Of Concept Data Supporting Development Of Treatment For Undisclosed Liver Target In Poster Presentation At ASGCT Annual Meeting
EDITMay 13, 2025
Read more →Editas Medicine Q1 EPS $(0.92) Misses $(0.59) Estimate, Sales $4.66M Beat $706.00K Estimate
EDITMay 12, 2025
Read more →Editas Medicine Announces U.S. Court Of Appeals Of Federal Circuit Remands CRISPR Patent Interference To Patent Trial And Appeal Board
EDITMay 12, 2025
Read more →Editas Medicine Announces Five Abstracts At 28th Annual Meeting Of American Society Of Gene And Cell Therapy
EDITApril 28, 2025
Read more →HC Wainwright & Co. Initiates Coverage On Editas Medicine with Buy Rating, Announces Price Target of $3
EDITApril 28, 2025
Read more →Editas Medicine CFO Erick Lucera To Step Down To Pursue Another Opportunity; Amy Parison Appointed As CFO
EDITMarch 20, 2025
Read more →Editas Medicine Q4 2024 GAAP EPS $(0.55) Misses $(0.38) Estimate, Sales $30.604M Miss $32.230M Estimate
EDITMarch 5, 2025
Read more →Peering Into Editas Medicine's Recent Short Interest
EDITFebruary 25, 2025
Read more →Editas Medicine Announces In Vivo Preclinical Proof Of Concept In HSC And Liver Cells, 2025 Milestones, And Strategic Priorities Through 2027 With Operational Runway Into Q2 2027
EDITJanuary 13, 2025
Read more →Chardan Capital Maintains Buy on Editas Medicine, Maintains $12 Price Target
EDITNovember 5, 2024
Read more →RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $5
EDITNovember 5, 2024
Read more →Stifel Maintains Buy on Editas Medicine, Lowers Price Target to $11
EDITNovember 5, 2024
Read more →Truist Securities Maintains Buy on Editas Medicine, Lowers Price Target to $8
EDITNovember 5, 2024
Read more →Wells Fargo Maintains Overweight on Editas Medicine, Lowers Price Target to $7
EDITNovember 5, 2024
Read more →Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $5
EDITNovember 5, 2024
Read more →Editas Medicine Q3 EPS $(0.75), Inline, Sales $61.00K Miss $2.25M Estimate
EDITNovember 4, 2024
Read more →Editas Medicine: Q1 Earnings Insights
EDITEditas Medicine (NASDAQ:EDIT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
May 4, 2022
Read more →Editas Medicine Q1 EPS $(0.74) Beats $(0.79) Estimate
EDITMay 4, 2022
Read more →Editas Medicine Earnings Conference Call Is Coming Up, Here's What You Need To Know
EDITEditas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to access the live webcast.
April 28, 2022
Read more →